Home > Patients > Complications
Potential Complications
What are the Complications From the Treatment?
Digestive System
There have been no digestive system complications reported when
Ablatherm® HIFU was used in the initial treatment of T-1
or T-2 cancer of the prostate. In the cases where Ablatherm® HIFU
was used in patients with previous radiation treatment failures,
there were some reports of mild rectal burning.
Urinary System
Narrowing of the urethra where it passes through the prostate
can appear in the months following the treatment due to the
scar tissue which normally replaces the treated prostate tissue.
This narrowing can necessitate a simple treatment called a
transurethral urethrotomy to re-establish the normal urethral
channel.
Almost all reports of incontinence are mild and can generally
be managed with drugs and/or muscle training. Most of the symptoms
are resolved in an average of one month.
Sexual Activity
When sexual impotence occurs, it is usually responsive to pharmacologic
treatment (Viagra, Levitra, or Cialis). There is evidence that
the use of these oral medications after treatment will help
to enhance healing. Following a period of 6 to 12 months after
treatment, potency will spontaneously be recovered in many
cases.
Summary of Ablatherm® HIFU Complications Reported
Throughout the World
The chart below describes the complications of using the Ablatherm® HIFU
device for treatment as primary care of localized prostate cancer
based on experience from around the world:
| Death |
0% |
| Digestive complications |
0% |
| Mild to moderate urinary
incontinence |
8% |
| Total urinary incontinence |
< 1% |
| Urethral stenosis |
8% |
| Sexual impotence with
nerve-sparing procedure |
20% |
| Sexual impotence without
nerve-sparing procedure |
66% |
|